

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating a disorder in which [aberrant] increased cell division occurs in a human or animal comprising administering to said human or animal a therapeutically effective amount of a peptide comprising the amino acid sequence:

$X_1 X_2 X_3 W M X_4 X_5 X_6 X_7;$

wherein:

~~[the sequence X_4 to X_7 is an amino acid sequence comprising at least 9 amino acids, which may optionally be interrupted by one or two amino acid residues between one or more of the 9 amino acid positions defined herein:]~~

X_1 is selected from W, T, PE, KQI, VV, PQT, H, RI and absent;

X_2 is ~~[an amino acid with an aromatic side chain]~~ Y;

X_3 is P ~~[or D]~~;

X_4 is ~~[an amino acid with a basic side chain]~~ K or R;

X_5 is ~~[an amino acid with a charged side chain]~~ K, R or E;

X_6 is ~~[an amino acid with a charged side chain]~~ H, R, Q or K; and

X_7 is ~~[an amino acid with a basic side chain or Serine]~~ H, S, R or K.

2. (Cancel)

3. (Cancel)

4. (Cancel)

5. (Cancel)

6. (Cancel)

7. (Cancel)

8. (Cancel)

9. (Currently Amended) The method according to claim 8.1 wherein said peptide X_1 to X_7 has the amino acid sequence W Y P W M K K H H R (SEQ ID NO:7).

10. (Withdrawn) The method according to claim 1 wherein said peptide further comprises a cell penetration moiety.

11. (Withdrawn) The method according to claim 10 wherein said cell penetration moiety is linked directly to the carboxy-terminal of the peptide X1 to X7.

12. (Withdrawn) The method according to claim 10 or 11 wherein said cell penetration moiety has the amino acid sequence:

X8 Q I K I W F Q N R R M K W K K

wherein X8 is R or Q.

13 (Withdrawn) The method according to claim 10 wherein said cell penetration moiety has the amino acid sequence

X8 Q X9 X10 X11 W F Q N X12 X13 M X14 W X15 X16

wherein

X8 is R or Q,

X9, X11 are each independently I or L, and

X10, X12, X13, X14, X15 and X16 are each independently K or R

14 (Currently Amended and Withdrawn) A method according to claim 10 wherein said cell penetration moiety has the amino acid sequence:

QIRIWFQNRRMKWKK; [SEQ ID NO: 10]

QIKIWFQNKRKMWKKK; [SEQ ID NO: 11]

QIKIWFQNKKMKWKK; [SEQ ID NO: 12]

QIRIWFQNRRKMKWKK; [SEQ ID NO: 13]

QIRIWFQNRRMRWKK; [SEQ ID NO: 14]

QIRIWFQNRRMKWRK; [SEQ ID NO: 15]

QIRIWFQNRRMKWKR; [SEQ ID NO: 16]

QIRIWFQNRRMKWRR; [SEQ ID NO: 17]

QIRIWFQNRRMKWKK; [SEQ ID NO: 18]

QIKIWFQNRRMKWRK; [SEQ ID NO: 19]
QIRIWFQNKRKMWRK; [SEQ ID NO: 20]
QIKLWFQNRRMKWKK, [SEQ ID NO: 21]
QLKLWFQNRRMKWKK; [SEQ ID NO: 22] or
QLRIWFQNRRMKWKK. [SEQ ID NO: 23]

15. (Currently Amended and Withdrawn) A method according to claim 10 wherein said peptide has the sequence:

W Y P W M K K H H R Q I K I W F Q N R R M K W K [SEQ ID NO: 26]; or

W Y P W M K K H H R Q I K I W F Q N R R M K W K K. [SEQ ID NO: 24]

16. (Currently Amended) The method according to claim 1 wherein said peptide has the sequence

W Y P W M K K H H R (SEQ ID NO:7).

17. (Previously Presented) The method according to claim 1 wherein said disorder is a cancer.

18. (Currently Amended) The method according to claim 1 wherein said cells in which increased cell division occurs express one or more Hox genes.

19. (Currently Amended) The method according to claim 1 wherein PBX does not act as an oncogene in said cells in which increased cell division occurs.

20.-25. (Cancel)

26. (Withdrawn) A method according to claim 1 wherein said human or animal is also administered a cytotoxic or chemotherapeutic agent.

27. (Cancel)

28.-33. (Cancel)

34. (Cancel)

35. (Cancel)